First-line and second-line antiretroviral therapy

Free article

Comment

Alexandra Calmy et al. Lancet. 2004 Jul.

Free article

. 2004 Jul;364(9431):329; author reply 330.

doi: 10.1016/S0140-6736(04)16716-0.

No abstract available

Comment on

Antiretroviral therapy for previously untreated HIV-1-infected adults: 2NN, or just one?
Carr A. Carr A. Lancet. 2004 Apr 17;363(9417):1248-50. doi: 10.1016/S0140-6736(04)16028-5. Lancet. 2004. PMID: 15094265 No abstract available.
Comparison of first-line antiretroviral therapy with regimens including nevirapine, efavirenz, or both drugs, plus stavudine and lamivudine: a randomised open-label trial, the 2NN Study.
van Leth F, Phanuphak P, Ruxrungtham K, Baraldi E, Miller S, Gazzard B, Cahn P, Lalloo UG, van der Westhuizen IP, Malan DR, Johnson MA, Santos BR, Mulcahy F, Wood R, Levi GC, Reboredo G, Squires K, Cassetti I, Petit D, Raffi F, Katlama C, Murphy RL, Horban A, Dam JP, Hassink E, van Leeuwen R, Robinson P, Wit FW, Lange JM; 2NN Study team. van Leth F, et al. Lancet. 2004 Apr 17;363(9417):1253-63. doi: 10.1016/S0140-6736(04)15997-7. Lancet. 2004. PMID: 15094269 Clinical Trial.